• MedTech and Biotech Deals – 18 May

    Here is Matt Lowdon‘s weekly deals update, covering news across Medical Technology and Life Sciences. News includes CAR-T, AI Scientists, urology, and more.

    ➡️ NeuroVision Imaging, Inc., which is working toward regulatory approval for its early Alzheimer’s detection technology, has acquired fellow diagnostics maker Durin Life Sciences Inc. for an undisclosed price.

    ➡️ As the wave of in vivo CAR-T hype crests, CREATE Medicines is catching the swell with a $122 million series B meant to back its early pipeline of autoimmune and cancer candidates.

    ➡️ Fosun Pharma has paid $60 million for an option on AriBio’s late-phase Alzheimer’s disease program, securing the chance to expand its rights to the asset in exchange for a further $80 million.

    ➡️ AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence, inking a three-year licensing deal with OWKIN to leverage its autonomous “AI Scientist” platform.

    ➡️ Alphabet’s AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model

    ➡️ FUJIFILM Healthcare Americas Corporation has signed a deal with Ardent Health to bring its enterprise imaging software to hospitals and clinics in six states.

    ➡️ Cambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.

    ➡️ INFEX Therapeutics has raised £4.3 million to advance an anti-infective pipeline led by a midphase drug candidate.

    ➡️ UroMems, a worldwide leader in medical technology and mechatronic solutions for urology, has secured $60 million in a strategic round of funding

    ➡️ Drummond Scientific Company, a leading manufacturer of medical technology, diagnostic, and sample collection devices, has announced the acquisition of Accu-Glass LLC, a Drummond Scientific Company,

    ===============

    Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close